Home / Businesswire / Hikma Acts to Ease Critical Shortage of Pain Medications Needed by US Hospitals and Their Patients

Hikma Acts to Ease Critical Shortage of Pain Medications Needed by US Hospitals and Their Patients

Leading Generic Pharmaceutical Company Increases Manufacturing
Capacity to Produce and Release Significant Quantities of Scarce
Medicines

EATONTOWN, N.J.–(BUSINESS WIRE)–Hikma Pharmaceuticals PLC (the Hikma Group) (LSE: HIK) (NASDAQ Dubai:
HIK) (OTC: HKMPY), the multinational generic pharmaceutical company,
announced today that its US business has begun releasing significant
quantities of hydromorphone to US hospital customers to help ease a
current shortage of injectable opioids used to treat patients.

In response to this shortage, Hikma released more than five million
hydromorphone 2ml vials to US hospitals during June, and expects to
release another three million vials during July. The current US hospital
shortage of injectable opioids used for patient pain management occurred
when a significant supplier to the US market temporarily ceased
manufacturing.

Daniel Motto, Executive Vice President of Hikma’s US Injectables
Division, commented: “We continue to prioritize the manufacture of
opioid products affected by this shortage including fentanyl,
meperidine, morphine and hydromorphone to provide hospitals and doctors
with the medicines they need to best treat their patients.”

“We have the capacity in our FDA-inspected manufacturing facility in
Cherry Hill, New Jersey for all CII opioid injectable products, and
believe we can now address the current shortage of these vital and
urgently needed medications, pending increased quota allowances from the
US Drug Enforcement Administration.”

For more information about our US business, please visit www.hikma.com/us

— ENDS —

About Hikma

Hikma helps put better health within reach every day for millions of
people in more than 50 countries around the world. For 40 years, we’ve
been creating high-quality medicines and making them accessible to the
people who need them. We're a global company with a local presence
across the United States (US), the Middle East and North Africa (MENA)
and Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform people's
lives. We're committed to our customers, and the people they care for,
and by thinking creatively and acting practically, we provide them with
a broad range of branded and non-branded generic medicines. Together,
our 8,500 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner in the
MENA region, and through our venture capital arm, are helping bring
innovative health technologies to people around the world. For more
information, please visit www.hikma.com.

Contacts

Hikma Pharmaceuticals PLC
Steven H. Weiss
Senior
Director, US Communications and Public Affairs
+1 732 542 1191/ +1
917 374 2024
or
Brooke Clarke
Vice President Corporate
Affairs
+44 (0)20 7399 2795/ +44 (0)7970 338 250
or
Virginia
Spring
Investor Relations Manager
+44 (0)20 3892 4389/ +44
7973 679502
or
FTI Consulting
Ben Atwell/Brett
Pollard/Andrew Ward
+44 (0)20 3727 1000